ResMed Shifts Executive Stock Awards To Earnings And Revenue Goals, Caps Payouts At 200%
Shareholder returns will still adjust awards, while Ronald Taylor's retirement reduced the board to 10 directors from 11.
ResMed, which makes devices and software for sleep and breathing conditions, approved executive stock awards Thursday that put earnings and revenue goals at the center of pay. The fiscal 2027 awards replace a stock-return-based design and cap earned shares at 200% of target, according to the company's Thursday SEC filing.
Financial Goals Set The Starting Payout
The compensation committee will give adjusted earnings per share and adjusted revenue equal weight over three fiscal years beginning in fiscal 2027. Each year receives one-third of the target award, divided equally between the metrics.
Executives earn nothing for a metric that misses its minimum goal. Meeting that minimum pays 50% of the shares allocated to the metric; hitting the target pays 100%, and reaching the maximum pays 200%. Results between those points produce proportionate payouts.
The annual results are averaged to establish the financial payout. Recent awards instead depended on ResMed's own shareholder return and its performance relative to other companies.
Stock Returns Still Adjust The Award
ResMed's shareholder return ranking against companies in the S&P 500 will multiply the financial payout by between 0.75 and 1.25. That comparison runs for three years from the grant date.
The multiplier is 0.75 at or below the 25th percentile, 0.95 at the 50th, 1.00 at the 60th and 1.25 at or above the 75th. Intermediate rankings receive proportionate adjustments, but the final award cannot exceed twice the target shares.
Executives generally must stay employed until the committee certifies performance after the measurement period. Death or disability pays the target award. Qualifying retirement—age 60 or older and at least five years of continuous service—preserves eligibility for a prorated award based on actual results.
Certain dismissals without cause or resignations for good reason also preserve prorated eligibility from the grant's second anniversary. In a change of control, awards retained or replaced convert to time-based shares using the greater of target or the specified performance calculation. Those shares generally vest on the third grant anniversary, subject to employment and qualifying departure exceptions; awards not retained or replaced vest immediately before the transaction.
Taylor Leaves A Smaller Board
Director Ronald Taylor's term ended Wednesday after he opted against re-election, and ResMed reduced its board to 10 directors from 11. His decision had been reported on August 17, 2026.
Shareholders elected all 10 nominees through the 2027 annual meeting. They also approved executive pay in an advisory vote, casting 95,067,879 votes for and 12,883,333 against, and ratified PricewaterhouseCoopers as auditor for the fiscal year ending June 30, 2027.
ResMed's business spans Sleep and Breathing Health and Residential Care Software. Its CPAP machines use pressurized air delivered through a mask to keep patients' airways open during sleep; its software serves home medical equipment, home health, hospice, nursing and senior living providers.
Devices accounted for about 51% of fiscal 2026 net revenue, while masks, diagnostics and accessories contributed about 37%.
The new awards tie the initial share payout to financial results, while relative stock performance retains a direct role in the final amount executives receive.
Sources
- 8-K Filing — RESMED INC (RMD) — SEC EDGAR